Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05212428 · ClinicalTrials.gov registry record · NA
DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study
A NA study of Genetic Disorder, sponsored by Mayo Clinic.
- Active
- Registry status
- NA
- Development phase
- 110,000
- Enrollment target
- 3
- Study locations
NCT05212428: Active NA study of Genetic Disorder, sponsored by Mayo Clinic.
NCT05212428 is a NA study of Genetic Disorder that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 110,000 participants, above the 198-participant average among 5 other Genetic Disorder trials with a reported enrollment target (55456% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05212428, a NA study of Genetic Disorder, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 110,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial collects information on how sequencing a patient's deoxyribonucleic acid (DNA) (i.e., the genetic material) could impact their health care. This study also develops and improves ways to include genomic information from DNA sequencing into the electronic health record to create a more complete "Health Tapestry" for each participant. Sequencing of a patient's DNA leads to the detection of genetic variants some of which determine risk for disease development. Discovery of those genetic variants in a patient could result in prevention, earlier diagnosis or better therapy of disease.
Primary Outcome
Patients will be asked to complete a family history as part of this study. The family history will be assessed to determine the percentage of participants with evidence of genetic risk for the actionable finding. Standard descriptive statistics approaches will be used for analysis.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- OTHER Diagnostic Laboratory Biomarker Analysis
- OTHER Genetic Counseling
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110,000 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT05212428 still lists
NCT05212428 is an interventional study that assigns participants to a tested intervention. Its 110,000 participants enrollment target places it among the larger protocols in the corpus, above the 198-participant average among 5 other Genetic Disorder trials with a reported enrollment target (55456% higher).
The record links to 1 condition, with Genetic Disorder appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT05212428 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05212428 about?
NCT05212428 is a clinical study titled "DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study". This clinical trial collects information on how sequencing a patient's deoxyribonucleic acid (DNA) (i.e., the genetic material) could impact their health care. This study also develops and improves ways to include genomic information from DNA sequencing into the electronic health record to create a ...
What is the current status of trial NCT05212428?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 110,000 participants. The study started on 2020-01-22. Estimated completion is 2026-12-31.
What conditions does trial NCT05212428 study?
This clinical trial studies the following conditions: Genetic Disorder.
What interventions are being tested in trial NCT05212428?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Diagnostic Laboratory Biomarker Analysis (OTHER), Genetic Counseling (OTHER).
Who is sponsoring clinical trial NCT05212428?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05212428 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Inherited Reproductive Disorders
RECRUITING
-
Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes
ACTIVE NOT RECRUITING
-
Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
ACTIVE NOT RECRUITING
-
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
COMPLETED · Phase 1
-
Pediatric Patients With Metabolic or Other Genetic Disorders
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05804188 · 105,000 participants
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
- NCT02917460 · 102,000 participants · NA
Rady Children's Institute Genomic Biorepository
- NCT05741112 · 100,500 participants · NA
The Long COVID-19 Wearable Device Study
- NCT06251323 · 119,680 participants · NA
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI